- Girl Scout Cookies Teach Us All a Lesson on GMOs
We should all be proud of the Girl Scouts for standing up for science and rejecting demands from anti-GMO groups to alter the ingredients of Girl Scout Cookies. Whether we're fans of eating Samoas by the sleeve or investors, we can all learn from this.
- Why Investors are Excited About Intrexon and Ziopharm's New Deal
Ziopharm shares have soared over 50%, while Intrexon is up over 20%. What has investors so excited?
- General Electric to United Kingdom: Give Us Your Plutonium Stockpiles
In summer 2015, the government of the United Kingdom will decide the next step in its plans to dispose of its separated plutonium stockpiles. General Electric wants its advanced reactor design to go head-to-head with the competition.
- Why Amyris Is My Favorite Stock to Buy in 2015
Falling production costs will allow Amyris to double production capacity in 2015, and likely again in 2016, while also allowing the company to profitably enter multiple markets. Time to take a closer look.
- 5 Crazy Habits You Might Adopt With Low-Cost Genome Sequencing
A full human genome can now be sequenced for $1,000. That's still a little pricey for mass adoption, but Illumina and Pacific Biosciences could bring the cost down even further -- opening up the genomics floodgates.
- 7 Things You Need to Know About Solazyme's Flagship Product for 2015
Solazyme's Encapso drilling lubricants could seize a large and growing opportunity in oil and gas well drilling in 2015, but investors need to be realistic, too.
- Biotech in Your Starbucks? Move to Premium Coffees Could Make It Happen
Starbucks' biotech brews could take the competition to another level entirely -- and maintain the chain's commitment to sustainable sourcing.
- Why Monsanto Might Be the Best Internet of Things Stock
You may be awaiting the arrival of the smart refrigerator or toaster oven, but Monsanto is thinking bigger with the Internet of Things. In fact, the company's new software platform could make it the best Internet of Things stock on the market.
- Can Biotech Save Natural Gas Producers Billions in Flaring Costs?
Last year the United States ignited nearly $1 billion worth of natural gas because it didn't have the infrastructure required to capture and store it. While producers aren't incentivized to capture and flood the market with gas that is currently flared, biotech could provide a reliable and profitable solution.
- Solazyme Pivots Commercialization Strategy, But Does Amyris Do It Better?
Solazyme realized that it needs to sell high value products to survive, but Amyris realized that over 12 months ago. What can investors learn from execution at Amyris, and how does it translate to the new strategy at Solazyme?